Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease  by Haase, Volker H.
Oxygen regulates epithelial-to-mesenchymal
transition: insights into molecular mechanisms and
relevance to disease
Volker H. Haase1,2,3
1Department of Medicine, Vanderbilt School of Medicine, Nashville, TN, USA; 2Department of Cancer Biology, Vanderbilt School of
Medicine, Nashville, TN, USA and 3Molecular Physiology and Biophysics, Vanderbilt School of Medicine, Nashville, TN, USA
Epithelial-to-mesenchymal transition (EMT) is a
developmentally vital, molecularly complex cellular process
by which epithelial cells lose apico–basal polarity and
cell–cell contact, become motile, and acquire mesenchymal
characteristics. Under pathophysiological conditions EMT has
a central role in cancer progression and metastasis, and has
been associated with fibrotic disorders. Microenvironmental
changes such as alterations in oxygen levels and activation of
hypoxic signaling through hypoxia-inducible factor (HIF) are
emerging as important triggers and modulators of EMT.
Recent insights into potential molecular mechanisms
underlying oxygen-dependent regulation of this process and
their relevance to disease are discussed.
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Epithelial-to-mesenchymal transition (EMT) is a collective
term for a series of phenotypic and molecular events during
which epithelial cells lose apico–basal polarity and cell–cell
contact, become motile and acquire mesenchymal character-
istics. It is vital for normal morphogenesis and tissue
remodeling during the early and late stages of embryonic
development. The reverse event is called mesenchymal to
epithelial transition and occurs physiologically when primary
mesenchymal cells convert to secondary epithelial cells, for
example, during nephron formation. Under pathophysiolo-
gical conditions, EMT has been implicated in cancer
progression and metastasis, wound healing and the develop-
ment of fibrotic disorders, including pulmonary, hepatic and
renal fibrosis (for reviews see Kalluri, Liu, Thiery, Thiery and
Sleeman1–4). Phenotypically, EMT is characterized by the
organized disassembly of epithelial cell–cell contacts such as
adherens, tight and gap junctions, as well as desmosomes
leading to cell–cell separations, which in conjunction with a
dramatic actin cytoskeletal remodeling results in the transi-
tion to a spindle-shaped morphology coupled with increased
migratory ability. On the molecular level EMT is associated
with the loss of, or the redistribution of epithelial-specific
junctional proteins such as ZO proteins and cadherins, and
the de novo expression of mesenchymal markers, such as
vimentin, a-smooth muscle actin (aSMA), fibroblast-specific
protein 1 (FSP1/S100A4) and N-cadherin, and the expression
of matrix metalloproteinases.1–3
Several molecular signaling pathways trigger EMT during
embryonic development and/or under pathophysiological
conditions and have context-dependent roles in the EMT
process. These include signaling through (a) the activation of
receptor tyrosine kinases by hepatocyte growth factor (HGF),
fibroblast growth factor, and platelet-derived growth factor
involving the Erk mitogen-activated protein kinase-signaling
cascade, phosphatidylinositol-30-kinase controlled pathways,
and the Src-STAT-signaling pathway; (b) the activation of
transforming growth factor (TGF)-b receptor serine-threo-
nine kinases; and (c) the stimulation of the Notch and Wnt/
b-catenin pathways leading to the activation of transcription
factors CSL (C-promoter-binding factor 1/suppressor of
hairless/LAG1) and lymphoid enhancer factor/T-cell factor
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(LEF/TCF), respectively. EMT-triggering pathways contribute
to both gene regulation and cytoplasmic signaling, and
functional interaction between pathways can result in signal
amplification. Crucial nuclear targets are transcriptional
regulators, which upon activation mediate the repression of
epithelial proteins, such as E-cadherin and ZO-1, a central
event in EMT. Epithelial repressors include the zinc-finger
transcription factor snail homolog 1 (SNAI1, also known as
Snail) and snail homolog 2 (SNAI2, also known as Slug),
zinc-finger E-box binding homeobox (ZEB) 1 (ZFHX1A, also
known as dEF1), ZEB2 (ZFXH1B, also known as SMAD-
interacting protein 1 (SIP1)), twist homolog 1 (TWIST1)
and TCF3 (E2A immunoglobulin enhancer-binding factors
E12/E47).5,6
Recent reports have linked alterations in microenviron-
mental oxygen tension and the activation of hypoxia-
inducible factor (HIF) signaling to EMT. Potential molecular
mechanisms underlying oxygen-dependent regulation of
EMT in development and disease, and their relevance to
renal injury and the progression of chronic kidney disease
(CKD) are discussed.
OXYGEN-SENSING MECHANISMS IN THE REGULATION OF
EMT
Alterations in intracellular PO2 have profound effects on
cellular energy metabolism, proliferation, differentiation and
cell type-specific functions and result in well-orchestrated
molecular responses.7 Key intracellular oxygen sensors are 2-
oxoglutarate-dependent dioxygenases (prolyl-4-hydroxylase
domain (PHD) proteins), which target specific proline
residues of the hypoxia-inducible factor a-subunit (HIF-a)
for hydroxylation and require molecular oxygen, ferrous iron
and ascorbate (Figure 1). HIF hydroxylation is a prerequisite
for rapid proteasomal HIF inactivation under conditions of
normal oxygen tension. Inhibition of HIF-a degradation in
the presence of oxygen can result from the inherited or
somatically acquired inability of cells to hydroxylate HIF-a,
or from a defect in the ubiquitination of hydroxylated HIF-a
and its targeting for proteasomal degradation, which is the
case in hereditary leiomyomatosis and renal cancer syn-
drome, von Hippel-Lindau (VHL) disease or sporadic
tumors associated with loss of VHL tumor suppressor
function (for a review and relevant references see Haase8).
Furthermore, normoxic stabilization of HIF-a can be
achieved by pharmacological inhibition of PHDs with 2-
oxoglutarate analogs,9 or can be mediated by nitric oxide and
TNF-a, interleukin 1, angiotensin II, and a variety of growth
factors including epidermal growth factor, insulin and
insulin-like growth factors (for an overview and relevant
references see Haase8). Nitric oxide, reactive oxygen species,
v-Src and activated Ras have been shown to inhibit HIF
prolyl-hydroxylation.10,11
HIF transcription factors are members of the Per-ARNT-
Sim family of heterodimeric basic helix–loop–helix (bHLH)
transcription factors and consist of an oxygen-sensitive
a-subunit and a constitutively expressed b-unit, also known
as the aryl-hydrocarbon-receptor nuclear translocator
(ARNT) or HIF-b.11,12 As transcription factors HIF hetero-
dimers regulate the expression of gene products that have
essential roles in the control of anaerobic energy metabolism,
angiogenesis, cellular proliferation, apoptosis, differentiation,
and other biological processes, which ultimately allows cells
and tissues to adapt to and to survive an oxygen-deprived
environment. Although a large number of HIF transcrip-
tional targets are co-regulated by both HIF-1 and HIF-2,
individual HIF homologs carry out distinct biological func-
tions and regulate unique targets. This may be the result of
tissue-specific interactions with other nuclear factors, differ-
ential interactions with transcriptional co-factors or a
reflection of tissue and cell type-dependent differences in
the ratios of individual HIF-a protein levels (for review see
Ruas and Poellinger13). In addition to its role as a transcrip-
tion factor, which mediates the canonical hypoxia response
by binding to hypoxia response element (HRE) containing
DNA sequences and transcriptional co-activator recruitment,
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Figure 1 |Overview of HIF regulation. Under normoxia
hydroxylation of hypoxia-inducible factor (HIF)-a subunits by
prolyl-4-hydroxylases is required for binding to the pVHL-E3-
ubiquitin ligase complex, which poly-ubiquitinates HIF-a and
targets it for proteasomal degradation. When prolyl-4-
hydroxylation is inhibited HIFa is stabilized and translocates to the
nucleus where it heterodimerizes with HIF-b. HIF-a/b
heterodimers bind to the HIF consensus binding site RCGTG and
regulate transcription of HIF target genes, for example, EPO, VEGF,
and GLUT-1. Factor-inhibiting-HIF (FIH) is an asparagine
hydroxylase that modulates cofactor recruitment to the HIF
transcriptional complex through oxygen-dependent asparagine
hydroxylation of the HIF-a carboxy-terminal transactivation
domain. FIH also modulates the cross talk between Notch and HIF
pathways through Notch ICD hydroxylation.34 Non-canonical HIF
signaling occurs through functional interaction with other
proteins, such as the Notch intracellular domain (for a more
complete overview of HIF-a-interacting proteins see Wenger
et al.12). Nitric oxide, reactive oxygen species, the Krebs cycle
metabolites succinate and fumarate, cobalt chloride, and iron
chelators such as desferrioxamine are known to inhibit HIF prolyl-
4-hydroxylases in the presence of oxygen. Asn, asparagine; CoCl2,
cobalt chloride; EPO, erythropoietin; Fe2þ , ferrous iron; GLUT-1,
glucose transporter 1; HRE, hypoxia response element; NO, nitric
oxide; Notch ICD, Notch intracellular domain; VEGF, vascular
endothelial growth factor; ROS, reactive oxygen species.
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HIF-a subunits also regulate cellular functions through
molecular interactions with components of other signaling
pathways in an HRE-independent manner. These include
tumor suppressor protein p53, the c-Myc proto-oncogene
and the Notch intracellular domain.12,14–17 More recent
experimental data suggest that HIF has the ability to
modulate the activity of several EMT-triggering signaling
pathways, and that both the HRE-mediated HIF canonical
response, as well as non-canonical HIF-signaling events are
relevant to the EMT process (Figure 2).
HYPOXIA AND HIF MODULATION OF EMT-ASSOCIATED
SIGNALING PATHWAYS
It has now become apparent that hypoxia and HIF activation
have the potential of modulating the activity of major
EMT-triggering pathways by either regulating the expression
levels of EMT inducers and their receptors, by affecting the
expression levels of pathway associated signaling molecules
and downstream effectors, or by a signal enhancing func-
tional interaction with EMT-associated nuclear factors.
Members of the TGF-b family of growth factors are major
inducers of EMT during embryonic development, cancer
progression and in the pathogenesis of fibrotic disorders.18
Experimental evidence suggests that hypoxia increases the
expression levels of TGF-b,19–23 thus providing a potential
mechanism by which hypoxia may modulate TGF-b triggered
EMT. TGF-b binds to type I and type II receptor serine/
threonine kinases and regulates EMT responses through
complex mechanisms, which involve SMAD and non-SMAD
signals. Receptor SMADs, SMAD2 and SMAD3, are activated
following receptor trans-phosphorylation and form tran-
scriptional complexes with SMAD4. These regulate the
expression of gene products, which control cell proliferation,
differentiation, apoptosis, and migration. Non-SMAD-
mediated TGF-b signals activate the MAPK-signaling
cascade, phosphatidylinositol-30-kinase and regulate the
activity of small Rho family GTPases thereby influencing
motility (for a review on TGF-b signaling see Zavadil and
Bottinger18). TGF-b targets include the zinc-finger repressors
SNAI1 and SNAI2 the two-handed E-box-binding zinc-finger
protein ZEB2/SIP1 and bHLH transcriptional repressors HEY
(for further references see Nieto, Zavadil and Bottinger5,18).
Although the molecular mechanisms underlying functional
interactions between hypoxia and TGF-b signals are ill
defined, close proximity of HIF and SMAD-binding DNA
sequences in co-regulated target genes suggests that HIF and
TGF-b may cooperate on a transcriptional level as was
suggested for the regulation of VEGF expression.24 Further-
more, hypoxia increases SMAD3 mRNA levels and promotes
the thrombospondin-dependent release of latent TGF-b2,
thus activating TGF-b signaling,25 suggesting that hypoxia
may affect the TGF-b signaling pathway at multiple
regulatory levels. HIF and TGF-b also co-regulate gene
products that have been shown to trigger EMT, or whose
expression is increased as a result of the EMT process. For
example, HIF and TGF-b both induce plasminogen activator
inhibitor 1 (PAI1) and connective tissue growth factor
(CTGF).26–28 CTGF, a member of the CCN (CTGF/cysteine
rich 61/nephroblastoma overexpressed) family and mediator
of TGF-b’s profibrotic actions, regulates multiple biological
processes including cell adhesion and migration, extracellular
matrix (ECM) production, angiogenesis, tumor growth and
wound repair.29 It is rapidly induced by TGF-b in a SMAD-
dependent manner and is a transcriptional target of HIF-1 in
renal tubular epithelial cells.28 When added to cultured
epithelial cells or overexpressed, CTGF triggers an EMT
phenotype.30,31
Another important pathway that regulates EMT and is
influenced by hypoxia is the Notch-signaling pathway.17,32–34
Notch controls differentiation, cell fate specification,
proliferation and survival, and is important for stem cell
maintenance. It promotes EMT during cardiac valve devel-
opment and tumor progression through SNAI1 and SNAI2
induction,35 and is involved in TGF-b1/SMAD induced EMT
through HEY1.36 Following ligand binding, the pathway is
activated by proteolytic cleavage of the cytoplasmic tail of the
Notch transmembrane receptor, liberating the Notch in-
tracellular domain, which then translocates to the nucleus
where it converts CSL to an activating transcription factor.37
HIF-1a interacts with the Notch intracellular domain
functionally and increases its transcriptional activity. This
functional interplay between HIF and Notch appears to be
important for stem cell maintenance under hypoxia.17 In an
oncogenic context hypoxia augments Notch signaling causing
EMT changes as a result of increased SNAI1 expression.33
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Figure 2 |HIF regulation of EMT. Shown is a simplified overview
of EMT-triggering signaling pathways and their effectors, which
are modulated by HIF. CTGF, connective tissue growth factor;
CXCR4, chemokine receptor 4; LOX, lysyl oxidase; LOXL, lysyl
oxidase-like; PAI1, plasminogen activator inhibitor 1; TIMP-1,
tissue-inhibitor of metalloproteinase 1; Rtyr kinases, receptor
tyrosine kinases; SDF1, stromal cell–derived factor 1; SNAI1, snail
homolog 1; TCF3, transcription factor 3 (E2A immunoglobulin
enhancer-binding factors E12/E47); ZEB, zinc finger E-box binding
homeobox.
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Interestingly, Notch also appears to potentiate HIF-depen-
dent lysyl oxidase (LOX) expression, which in turn further
increases SNAI1 protein stability thereby amplifying Notch
signaling33 (see the following paragraph). The mechanisms
by which HIF enhances Notch signals, however, appear to be
cell-type dependent. In melanoma cells HIF-1 activation
enhances Notch signals by increasing Notch1 mRNA levels.38
Enhanced Notch ligand expression has also been found in
fibrotic kidney disease, indicating that the Notch pathway is
potentially linked to the pathogenesis of CKD,39 the role of
hypoxia and HIF activation in the context of this pathway
and CKD progression, however, remains to be determined.
To add to the complexity of potential mechanisms
underlying oxygen-regulated EMT, hypoxia and HIF have
been shown to modulate the activity of HGF and Wnt,40,41
which both are ligands for two major EMT-triggering
signaling pathways. Although hypoxia suppresses b-catenin-
mediated transcriptional activity (HIF-1a competes with
TCF4 for b-catenin binding), b-catenin enhances HIF-1-
mediated transcription.41 With regard to HGF, HIF enhances
HGF signaling through a HIF-dependent increase in c-met
receptor tyrosine kinase expression in tumor cells.40 HGF is a
major inducer of EMT during normal development and in
cancer, and regulates cell motility by cell adhesion disas-
sembly, ECM and basement membrane degradation and by
altering the interactions between integrins and matrix
components. In the context of chronic renal injury, however,
HGF functions as an inhibitor of TGF-b triggered EMT and
attenuates the development of renal fibrosis.2
The composition and integrity of the basement membrane
is crucial for the maintenance of epithelial homeostasis, and
its disruption is a key event in EMT associated with cancer
metastasis and invasion, or fibrogenesis. In the kidney,
transitioned tubular epithelial cells would migrate into the
interstitium, produce ECM as myofibroblasts and thereby
participate in the progression of renal fibrosis. These events
are likely to be modulated by HIF activation through altered
expression of proteins that regulate cell migration and ECM
turnover. For instance, HIF has been shown to influence cell
migration through the regulation of avb3 integrin cell surface
expression42 and the induction of chemokine receptor
CXCR4 and its ligand stromal cell–derived factor-1 (SDF-1/
CXCL12), both of which have important functions in tumor
metastasis and the homing of progenitor cells (for review see
Chan and Giaccia43). Other relevant HIF-regulated proteins
in this context include ECM modifiers PAI1, urokinase
plasminogen activator receptor, TIMP1, matrix metallopro-
teinase (MMP)1 and MMP2,19,27,44,45 all of which contribute
to the pathogenesis of renal fibrosis.
HIF REGULATION OF EMT-ASSOCIATED TRANSCRIPTIONAL
REPRESSORS
A central event in EMT is the activation of epithelial
repressors, which act as downstream effectors of EMT-
triggering pathways. Epithelial repressors are transcription
factors, which recruit specific chromatin-remodeling
complexes and downregulate the expression of gene products
that are important in the maintenance of the epithelial
phenotype. These include cadherins, claudins, cytokeratins,
mucins, plakophilin, occludin, and ZO proteins (for a recent
review see Peinado et al.6). The loss of E-cadherin expression
is consistently observed during EMT and is an important
event during this process. E-cadherin is a key component of
cell–cell adhesion junctions and is essential for the formation of
epithelia during embryonic development and for the main-
tenance of adult epithelial homeostasis, and its loss is associated
with tumor cell invasiveness.6 Some epithelial repressors can
also directly or indirectly induce mesenchymal genes and gene
products that are important in matrix remodeling as demon-
strated by overexpression studies. So does activation of
zinc-finger containing transcriptional repressor SNAI1, which
indirectly increases MMP2 and MMP9 expression, as well as
the expression of TIMP1 and PAI1.46–48
There is growing experimental evidence that HIF mod-
ulates EMT by regulating the expression and activity levels of
major transcriptional repressors. Imai et al.49 observed that
SNAI1 was increased by hypoxia in ovarian cancer cells,
which correlated with increased HIF-a levels and decreased
E-cadherin expression. HIF control of EMT-inducing epithe-
lial repressors was subsequently demonstrated in normoxic
renal cancer cells that were defective in the VHL tumor
suppressor pVHL.50,51 pVHL is the substrate recognition
component of the E3 ubiquitin ligase that targets hydro-
xylated HIF-a for ubiquitination and subsequent proteaso-
mal degradation (Figure 1) and functional loss of pVHL
results in constitutive activation of HIF signaling. In pVHL-
deficient renal cancer cell lines Krishnamachary et al.50
reported that HIF-1 activation was associated with decreased
E-cadherin expression, led to the loss of cell–cell adhesion
and promoted EMT through the induction of transcriptional
repressors TCF3, ZEB1/dEF1, and ZEB2/SIP1. Similarly,
Evans et al.51 proposed that inactivation of pVHL resulted
in E-cadherin suppression through HIF-dependent induction
of SNAI1 and ZEB2/SIP1, whereas Esteban et al.52 suggested
that HIF-2 may have a more potent suppressive effect on
E-cadherin levels than HIF-1. SNAI1 and ZEB2/SIP1 are
highly expressed in E-cadherin-deficient carcinoma cells
where they promote tumor cell invasion and bind to
E-boxes in the minimal E-cadherin promoter with similar
suppressor effect.53–55
TWIST is an EMT-inducing bHLH transcription factor,
which represses E-cadherin through E-boxes that are also
targeted by SNAI1 and ZEB2/SIP1. During embryogenesis
TWIST governs gastrulation and mesoderm specification,
and when activated in tumor cells it promotes metastasis.56
TWIST is directly HIF regulated in Caenorhabditis elegans57
and in mammalian cells,57,58 and mediates hypoxia/HIF-
induced EMT in breast cancer, nasopharyngeal cancer and
lung tumor cells. TWIST-regulated migration and invasion of
hypoxic tumor cells was non-redundant with co-exist-
ing SNAI1-regulated migration and invasion, that is, an
additional reduction in migratory and invasive ability was
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achieved by knockdown of SNAI1 when TWIST was
inhibited.58 In head and neck cancers HIF-1a, TWIST and
SNAI1 expression correlated with metastasis and poor
clinical prognosis.58 HIF-1 activation in primary renal
epithelial cell culture enhanced the transition of epithelial
cells towards a mesenchymal phenotype; however, increased
transcription of the aforementioned epithelial repressors was
not observed with exposure to short-term hypoxia, which
may be a reflection of cell-type and context-dependent
differences in hypoxic gene regulation, or the duration of
hypoxia exposure.59
HIF-1 induction of LOX and lysyl oxidase-like (LOXL)-2
has been shown to promote migration in primary renal
epithelial cells, human breast and cervical cancer cells, and to
regulate E-cadherin expression in renal cell cancer.59–61
Although initially identified by their ability to cross-link
collagen and elastin fibers, LOX and LOXL proteins carry out
intracellular functions and display a range of biological
activities that extend beyond extracellular cross-linkage.
These include the regulation of ras- and NF-kB-signaling,
possibly through the modification of DNA-histone and
histone–histone interactions.62,63 A recent report by Peinado
et al.64 indicated that LOXL2 and LOXL3 have the potential
to regulate EMT by stabilizing and promoting the activity of
transcriptional repressor SNAI1. Because LOX and LOXL2
are HIF regulated, LOXL-mediated control of SNAI1 activity
may represent an additional molecular mechanism that
underlies oxygen-dependent epithelial repression, which
could be relevant to EMT in primary renal tubular epithelial
cells and to the pathogenesis of renal fibrosis.59,65 Post-
translational regulation of SNAI1 was also shown in head and
neck cancer cells, where both SNAI1 protein levels as well as
its activity were induced by hypoxia through HIF-1, whereas
SNAI1 mRNA levels did not change.58 Whether this involved
LOX or LOXL remains to be investigated.
HYPOXIA, HIF AND OXYGEN-REGULATED EMT IN CHRONIC
KIDNEY DISEASE
The molecular study of cancer, where hypoxia and HIF
stabilization correlate with poor clinical outcome and
resistance to therapy,43 has provided new and exciting
mechanistic insights into oxygen-dependent regulation of
EMT. Although it is unclear at the moment to which degree
these findings are applicable to the pathogenesis of CKD, they
are of great interest to experimental and clinical nephro-
logists and will certainly stimulate further investigations
into the role of chronic hypoxia, HIF signaling and EMT in
CKD progression. Notwithstanding the need for additional
clinical and experimental studies, the presence of hypoxia
(comparison to healthy controls) and HIF stabilization has
been clearly demonstrated in chronic renal diseases of
different etiologies (for example, diabetic nephropathy, IgA
nephropathy, unilateral ureteral obstruction (UUO), 5/6
nephrectomy, anti-Thy1 glomerulonephritis and others) both
in patients and in animal models employing blood oxygen
level-dependent (BOLD) MRI, immunohistochemical,
immunoblot, and PCR techniques, and by direct measurement
of renal tissue oxygen levels using microelectrodes (for an
overview of these studies see Haase, Eckardt et al., Heyman
et al., Fine and Norman, Nangaku et al.8,66–69). Renal hypoxia
associated with CKD is thought to result from a combination
of structural and functional changes, which include capillary
rarefaction, compromise of peritubular blood flow resulting
from glomerular injury, vasoconstriction from altered levels of
vasoactive factors and signaling molecules (for example,
angiotensin II, endothelin, nitric oxide), luminal narrowing
of atherosclerotic vessels, increased oxygen demand from
hyperfiltration and tubular hypertrophy, limited oxygen
diffusion as a consequence of ECM expansion, and renal
anemia66–68 (Figure 3). In diabetic nephropathy for example,
the clinical finding of increased HIF-1a expression in renal
biopsy material59 is consistent with decreased renal oxygena-
tion detected in experimental animal models by MRI.70,71
Moreover, the degree of HIF expression appears to correlate
with severity of injury,59 suggesting that the reduction in renal
tissue oxygen tension is more pronounced in advanced
diabetic nephropathy than in early disease.
Recent experimental evidence indicates that hypoxia may
accelerate CKD progression through its effects on renal cell
survival, inflammatory cell recruitment, collagen gene
expression, ECM turnover, and EMT8,67–69 (Figure 3). Our
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Figure 3 |Potential profibrotic role of HIF activation in chronic
kidney disease (CKD). Shown is a simplified overview of
functional and structural causes of hypoxia in CKD. As a result of
hypoxia, activation of hypoxia-inducible factor (HIF) signaling in
renal cells has the potential to promote renal fibrosis and to
contribute to the progression of CKD as demonstrated
experimentally in proximal tubule-specific HIF-1a knockout mice
(unilateral uretal obstruction model) and in mice with increased
tubular HIF-1a expression.59,72 HIF may exert its profibrotic
function by modulating cellular and molecular events that have
key roles in the pathogenesis of renal fibrosis. These include
extracellular matrix production and processing through regulation
of matrix-modifying factors and enzymes, such as CTGF, PAI1,
TIMP1, and MMPs, the modulation of EMT-triggering pathways,
and inflammation.
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laboratory has identified tubular epithelial HIF-1a as a
promoter of renal fibrosis in experimental UUO59 and
demonstrated that genetic inactivation of HIF-1a in the
proximal renal tubule led to a reduction in collagen
accumulation, inflammatory cell infiltration and the number
of FSP1-expressing interstitial cells.59 The notion of epithelial
HIF-1a as a profibrotic factor is supported by overexpression
studies in vivo.72 In addition, we and others have shown that
hypoxia and HIF activation promotes EMT and cell motility
of renal epithelial cells in vitro,59,73 which is likely to
contribute to HIF’s fibrogenic role in vivo. EMT in the
setting of CKD is considered a disease promoting mechanism
by which renal tubular epithelial cells acquire a mesenchymal
phenotype and migrate into the interstitium, where they
together with resident cells produce ECM as myofibroblasts.2
Irrespective of their origin, the accumulation of myofibro-
blasts is closely correlated with the degree of interstitial
damage and the risk of disease progression. The degree to
which EMT contributes to the renal myofibroblast pool
however, is debated. In an experimental model of UUO-
induced fibrosis, which traced cells of epithelial origin by
genetic means, Iwano et al.74 suggested that up to 36% of
interstitial myofibroblasts are EMT-derived, approximately
15% from the bone marrow, whereas the rest is derived from
resident fibroblast proliferation. Others have suggested that
pericytes75 or endothelial cells76 can be major sources of
ECM-producing renal interstitial myofibroblasts. Lending
further support to the concept of disrupted epithelial
homeostasis as a key event in renal fibrogenesis are studies
in transgenic mice, which demonstrate that forced expression
of transcriptional repressor SNAI1 induces renal fibrosis.65
Clinically, it would be important however to unequivocally
determine the degree by which EMT contributes to
tubulointerstitial fibrosis in patients with CKD.
Pharmacologic targeting of EMT-triggering signaling
pathways such as the TGF-b pathway has been proposed as
a therapeutic strategy to inhibit CKD progression. For
example, HGF and bone morphogenic protein-7 (BMP-7),
which both target TGF-b signaling, attenuate renal fibrosis in
animal models (for review see Liu2). So does blockade of
angiotensin II which has been shown to inhibit EMT in
addition to its beneficial hemodynamic and other effects.2
Angiotensin II blockade may be especially of interest from the
viewpoint of hypoxia-mediated renal injury, as it improves
microvascular perfusion.77 It is unlikely that HIF itself may
become a therapeutic target in this context, mainly because it
regulates multiple biological processes, some of which have
been shown to be cytoprotective or have beneficial effects on
tissue perfusion (for example, HIF regulates the scavenging of
reactive oxygen species, nitric oxide synthesis and promotes
angiogenesis). Certain HIF-regulated proteins, however,
irrespective of their role in EMT, may be suited as drug
targets to retard CKD progression. Pharmacological inhibi-
tion of HIF-regulated lysyl oxidases, phenocopied the effects
of genetic HIF-1a inactivation on cell motility in vitro and on
fibrogenesis in vivo, suggesting that lysyl oxidases are
important contributors to the pathogenesis of renal fibrosis.
In keeping with this notion, increased LOXL2 expression was
found in renal biopsy tissues from patients with CKD
underscoring its relevance to the pathogenesis of CKD
irrespective of etiology.59 Whether pharmacological inhibi-
tion of lysyl oxidases is feasible in clinical practice to slow the
progression of CKD warrants further investigation. Notwith-
standing the profibrogenic role of epithelial HIF in vivo and
its function in the regulation of EMT-triggering pathways,
systemic inhibition of HIF degradation (for example, with
cobalt chloride or 2-oxoglurate analogs, which both inhibit
HIF prolyl-hydroxylases) has been shown to be cytoprotec-
tive not only in acute ischemia, but also in certain chronic
renal disease models (for an overview of studies see Haase,
Heyman et al., Fine and Norman, Nangaku et al.8,67,69). It is
unclear however, which cell type, biological process or HIF
homolog confers cytoprotection or aids in the preservation of
renal function. Cell type-specific genetic studies in mice,
which target individual HIF homologs are needed to better
understand the contributions of HIF transcription factors to
chronic renal injury.
SUMMARY AND OUTLOOK
HIF has emerged as an important modulator of epithelial
differentiation and cell fate, linking hypoxia to tumor
metastasis and invasion, and to fibrogenesis. It interfaces
with the EMT process at multiple regulatory levels, which
include functional interactions and co-operation with well-
established EMT triggering signaling pathways, the regulation
of epithelial repressor activity, and the direct or indirect
regulation of proteins that modify cell–matrix interactions
and facilitate motility and invasion. Although experimental
evidence for HIF regulation of EMT stems mainly from the
study of tumor cells, the underlying molecular mechanisms
that have been identified are relevant for normal embryonic
development, wound healing and fibrogenesis, as decreases in
tissue oxygen levels occur physiologically during embryogen-
esis, and are commonly associated with tissue injury and
repair. Certainly, additional experimental and clinical studies
are needed to (a) further understand the context-specific role
of HIF signaling in developmental and disease-associated
EMT, (b) to identify the relevant oxygen-sensitive signaling
pathways, and most importantly (c) to address whether HIF-
regulated signaling pathways can be targeted therapeutically
to improve the outcome of malignant and non-malignant
diseases that are commonly associated with EMT when tissue
oxygenation cannot be improved with currently available
pharmacological strategies.
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